Perlara, a South San Francisco, CA-based drug discovery platform company, closed a $7.4M round of equity financing.
Backers included Pivotal Capital Alpha, Al-Hamra Group, Radical Investments, Homebrew Ventures, Haystack Fund and existing investors, including Y Combinator. Novartis participated in the financing under the terms of its research collaboration with Perlara.
Led by founder and CEO Ethan Perlstein, PhD., Perlara is a public benefit corporation working to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. The company operates by embarking on discovery journeys called PerlQuests™ with families and patient organizations to develop treatments for rare diseases…
See the entire article.